Evidence map›Paper›PMID 32662870›Full record

ArticleBiotechnology and bioengineering2020

A new nodavirus-negative Trichoplusia ni cell line for baculovirus-mediated protein production.

Ajay B Maghodia, Christoph Geisler, Donald L Jarvis

Open access · greenAbstract read
In one paragraph

Article in Biotechnology and bioengineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ajay B MaghodiaGlycoBac, LLC, Laramie, Wyoming.ORCID 0000-0002-1636-2810
Christoph GeislerGlycoBac, LLC, Laramie, Wyoming.ORCID 0000-0002-6568-8745
Donald L JarvisGlycoBac, LLC, Laramie, Wyoming.ORCID 0000-0002-8104-7155
University of Wyoming · US

Funding

Engineering a new insect cell line for human-type protein glycosylationR43GM125397 · NIGMS · GLYCOBAC, LLC · PI BLAIR, CAROL D, JARVIS, DONALD L. · 2018 to 2018
$217k
NIGMS NIH HHS R43 GM125397
6 · The paper itself

Abstract

Cell lines derived from Trichoplusia ni (Tn) are widely used as hosts in the baculovirus-insect cell system (BICS). One advantage of Tn cell lines is they can produce recombinant proteins at higher levels than cell lines derived from other insects. However, Tn cell lines are persistently infected with an alphanodavirus, Tn5 cell-line virus (TnCLV), which reduces their utility as a host for the BICS. Several groups have isolated TnCLV-negative Tn cell lines, but none were thoroughly characterized and shown to be free of other adventitious viruses. Thus, we isolated and extensively characterized a new TnCLV-negative line, Tn-nodavirus-negative (Tn-NVN). Tn-NVN cells have no detectable TnCLV, no other previously identified viral contaminants of lepidopteran insect cell lines, and no sequences associated with any replicating virus or other viral adventitious agents. Tn-NVN cells tested negative for >60 species of Mycoplasma, Acholeplasma, Spiroplasma, and Ureaplasma. Finally, Tn-NVN cells grow well as a single-cell suspension culture in serum-free medium, produce recombinant proteins at levels similar to High Five™ cells, and do not produce recombinant glycoproteins with immunogenic core α1,3-fucosylation. Thus, Tn-NVN is a new, well-characterized TnCLV-negative cell line with several other features enhancing its utility as a host for the BICS.

Indexed as

LepidopteraAnimalsBaculoviridaeCell Culture TechniquesCell LineRecombinant ProteinsRecombinant Proteinsadventitious virusalphanodavirusbaculovirus-insect cell systemmassively parallel sequencingTn-NVNTrichoplusia ni cell line virus

Identifiers

PMID32662870
PMCPMC8007066
OpenAlexW3042870833

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.